Pila Pharma AB (publ) (PILA.ST) Research

Based in Sweden, PILA PHARMA AB (publ) is a pharmaceutical firm actively engaged in clinical development. The company's principal drug, XEN-D0501, is a TRPV1 antagonist which has successfully completed two phase 2a clinical studies aimed at treating type 2 diabetes. PILA PHARMA AB (publ) was founded in 2014 and maintains its headquarters in Malmö, Sweden.

Market snapshot

Symbol
PILA.ST
Price
$1.39
Day change
+1.84%
Market cap
$63.3M
P/E ratio
-4.93x
52-week range
1.024-3.93
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Active Biotech AB (publ) (ACTI.ST)
  • Alligator Bioscience AB (publ) (ATORX.ST)
  • Biovica International AB (publ) (BIOVIC-B.ST)
  • Iconovo AB (publ) (ICO.ST)
  • Luxbright AB (publ) (LXB.ST)
  • Nanologica AB (publ) (NICA.ST)
  • NextCell Pharma AB (NXTCL.ST)
  • OncoZenge AB (publ) (ONCOZ.ST)

Open Pila Pharma AB (publ) (PILA.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.